Placenta-derived mesenchymal stem cells ameliorate lipopolysaccharide-induced inflammation in RAW264.7 cells and acute lung injury in rats

Abstract

Acute lung injury (AH) is a severe lung syndrome with high morbidity and mortality, due to its complex mechanism and lack of effective therapy. The use of placenta-derived mesenchymal stem cells (pMScs) has provided novel insight into treatment options of ALI. The effects of pMScs on lipopolysaccharide (LPS)-induced inflammation were studied using a co-culture protocol with lPS-stimulated R A W 2 6 4 . 7 cells. An LPS-induced AH Sprague-dawley rat model was developed by intravenously injecting 7.5 mg/kg L P S, and intratracheal instillation of 1x105 pMScs was performed after administration of LPS to investigate the therapeutic poten¬ tial of these cells. pMScs ameliorated LPS-induced ALI, as suggested by downregulated pro-inflammatory cytokine tumor necrosis factor-a and increased anti-inflammatory cytokine interleukin-10 in both cell and animal models. Moreover, the protein and leukocyte cells in bronchoalveolar lavage fluid decreased at a rapid rate after treatment with pMScs. Histopathology demonstrated that pMScs alleviated the infiltration of inflammatory cells, pulmonary hyperemia and hemorrhage, and interstitial edema. In addition, pMSc reduced the LPS-induced expression of c-X-c motif chemokine ligand 12 in RAW264.7 macrophages and in lung tissue of ALI rats. This demonstrated that pMScs are therapeutically effective in LPS-induced ALI.